Sample menu:

Application of autologous periperal blood/apheresis derived expanded/activated Dendritic Cells, gamma delta T cells, Natural Killer (NK) cells, NKT cells, Activated T Lymphocytes, Cytotoxic T lymphocytes (CTLs) and Lymphokine Activated Killer (LAK) Cells have been in clinical practice in Japan for more than two decades. The focus of present work Autologous Immune Enhancement therapy (AIET) is based on reported clinical experiences well accepted by the scientific community.

We draw the Peripheral blood and/or Peripheral blood mononuclear cells (PBMNCs) by Apheresis of the cancer patients (during remission in patients who undergo chemotherapy). Our processing technology specifically expands lymphocytes and NK cells to a significantly greater extent and the same takes around 2-3 weeks. After expansion, the activated lymphocytes and NK cells are injected back to the patient intravenously wherein these cells act against the cancer cells effectively and recharge the immune system. To further improvise the outcome of immune cell based therapies, we have been working on enhancing the cytotoxicity of NK cells, and the options of combining them with monoclonal antibodies as well.


Click here for an illustration explaining AIET stepwise procedure.